| A novel Nrf2 pathway inhibitor sensitizes keap1-mutant lung cancer cells to chemotherapy D Zhang, Z Hou, KE Aldrich, L Lockwood, AL Odom, KT Liby Molecular cancer therapeutics 20 (9), 1692-1701, 2021 | 24 | 2021 |
| Synthesis, structure, properties, and cytotoxicity of a (quinoline) RuCp+ complex Z Hou, AS Vanecek, JJ Tepe, AL Odom Dalton Transactions 52 (3), 721-730, 2023 | 3 | 2023 |
| Exploring structural effects in a new class of NRF2 inhibitors Z Hou, L Lockwood, D Zhang, CJ Occhiuto, L Mo, KE Aldrich, HE Stoub, ... RSC Medicinal Chemistry 14 (1), 74-84, 2023 | 2 | 2023 |
| NRF2 INHIBITORS AND USES THEREOF K Liby, D Zhang, A Odom, Z Hou US Patent App. 18/548,058, 2024 | | 2024 |
| Modeling Complex Ligands for High Oxidation State Catalysis: Titanium Hydroamination with Unsymmetrical Ligands Z Hou, R Jena, TJ McDaniel, BS Billow, S Lee, HI Barr, AL Odom ACS catalysis 14 (8), 5531-5538, 2024 | | 2024 |
| Discovery of First-in-Class IRAK4 Scaffolding Inhibitors for the Treatment of Inflammatory Disorders Arthritis & Rheumatology 75, suppl 9, 2023 | | 2023 |
| Novel inhibitors of the NRF2 pathway also arrest lung cancer cells in G2/M CJ Occhiuto, L Lockwood, Z Hou, A Odom, K Liby Cancer Research 83 (7_Supplement), 529-529, 2023 | | 2023 |
| Preparation of pyridines and pyrazines as Nrf2 inhibitors and uses thereof cross-reference to related applications K Liby, D Zhang, A Odom, Z Hou US Patent WO2,022,183,034, 2022 | | 2022 |
